Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) has officially announced the pricing of its public offering of common stock and warrants. The offering consists of 6,666,667 shares priced at $1.50 per share, alongside Series G and Series H warrants to purchase an equivalent number of shares. Total gross proceeds from the transaction are expected to reach approximately $10 million before accounting for underwriting discounts and offering expenses. The company intends to utilize the net proceeds to advance the development of therapeutic candidates targeting unmet needs in central nervous system and cardiometabolic diseases. While the capital injection supports long-term R&D, the offering's pricing is expected to lead to share dilution for existing investors in the short term. The transaction is scheduled to close shortly, subject to customary closing conditions.
Sign up free to access this content
Create Free Account